Publications
5803 Results
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 1073); American Society of Clinical Oncology 2020 Annual Meeting, poster session
- Year
- 2020
- Research Committee(s)
- Early Therapeutics and Rare Cancers
- Study Number(s)
- S1609
Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Metaplastic Carcinoma of the Breast: DART (SWOG S1609, Cohort 36)
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 1001); American Society of Clinical Oncology 2020 Annual Meeting, oral
- Year
- 2020
- Research Committee(s)
- Breast
- Study Number(s)
- S1416
Results of a phase II randomized trial of cisplatin +/- veliparib in metastatic triple-negative breast cancer (TNBC) and/or germline BRCA-associated breast cancer (SWOG S1416)
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 7010); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion
- Year
- 2020
- Research Committee(s)
- Cancer Care Delivery
- Study Number(s)
- S1417CD
Cumulative Incidence of Financial Hardship in Metastatic Colorectal Cancer (mCRC) Patients (pts): Primary Endpoint Results for SWOG S1417CD
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr TPS10090); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster
- Year
- 2020
- Research Committee(s)
- Melanoma
- Study Number(s)
- S1801
S1801: A randomized phase II trial of adjuvant versus neoadjuvant pembrolizumab (PEM) for melanoma
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr TPS8067); American Society of Clinical Oncology 2020 Annual Meeting, TIPS poster
- Year
- 2020
- Research Committee(s)
- Lymphoma
- Study Number(s)
- S1826
An Intergroup Collaboration for Advanced Stage Classical Hodgkin Lymphoma (cHL) in Adolescents and Young Adults (AYA): SWOG S1826
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 9532); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Lung
- Study Number(s)
- S1403
Residual circulating tumor DNA (ctDNA) after two months of therapy predicts progression-free and overall survival in patients treated on SWOG S1403 with afatinib +/- cetuximab
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 5022); American Society of Clinical Oncology 2020 Annual Meeting, poster discussion
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1605
Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer: SWOG S1605 (NCT #02844816)
- Journal / Conference
- Leukemia & Lymphoma Oct;61(10):2442-2447
- Year
- 2020
- Research Committee(s)
- Lymphoma
- PMID
- PMID32452714
- Study Number(s)
- S0816
Potential Impact of Consolidation Radiation Therapy for Advanced Hodgkin Lymphoma: a Secondary Analysis of SWOG S0816
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 5523); American Society of Clinical Oncology 2020 Annual Meeting, poster
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216
Bone metabolism biomarkers (BMB) and progression-free survival (PFS) in men with metastatic hormone sensitive prostate cancer (HSPC): SWOG S1216, a phase III trial of androgen deprivation therapy (ADT) with or without orteronel
- Journal / Conference
- J Clin Oncol 38: 2020 (suppl; abstr 5506); American Society of Clinical Oncology 2020 Annual Meeting, oral
- Year
- 2020
- Research Committee(s)
- Genitourinary
- Study Number(s)
- S1216